Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
Entrada Therapeutics Reports Third Quarter 2024 Financial Results– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress –
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society– Additional positive data from the Company’s completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial –
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and DevelopmentBOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately.
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne -
Entrada Therapeutics Reports Second Quarter 2024 Financial Results– Generated positive data from the Phase 1 clinical trial of ENTR-601-44 for DMD, including dose-dependent plasma and muscle concentration, and exon skipping –
Entrada Therapeutics Announces $100 Million Registered Direct Offering– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm –
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments –
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceBOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, June 10, 2024, at 4:00 p.m. Eastern Time.
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQBOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York, NY. The fireside chat will be held on Monday, May 20, 2024, at 9:30 a.m. Eastern Time.
Entrada Therapeutics Reports First Quarter 2024 Financial Results– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 –
Entrada Therapeutics to Present at Upcoming Investor ConferencesBOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:
Entrada Therapeutics Promotes Nathan J. Dowden to President- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada’s operational growth -
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 –
Entrada Therapeutics Reports Third Quarter 2023 Financial Results– Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company –
Entrada Therapeutics to Present at Upcoming Investor ConferencesBOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community- In its inaugural year, DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to combat disparity and support people living with Duchenne -
Entrada Therapeutics to Present at Upcoming Investor ConferencesBOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the Company will participate in two investor conferences in September.
Entrada Therapeutics Appoints Gina Chapman to its Board of DirectorsBOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics.
Entrada Therapeutics Reports Second Quarter 2023 Financial Results– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 –
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceBOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA. The fireside chat will be held on Wednesday, June 14, 2023 at 10:40 a.m. Pacific Time/1:40 p.m. Eastern Time.
Vertex Pharmaceuticals Hits Record High on Strong Q1 EarningsVertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
